Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review

about

Down regulation of G protein-coupled receptor 137 expression inhibits proliferation and promotes apoptosis in leukemia cells.

P2860

Q49238627-35F9670F-8376-40C0-92FF-EFDB0EBD08B7

P2860

Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review

Item

http://www.wikidata.org/entity/Q26775622

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Efficacy of Dasatinib in a CML ...... e Report and Literature Review

@ast

Efficacy of Dasatinib in a CML ...... e Report and Literature Review

@en

Efficacy of Dasatinib in a CML ...... e Report and Literature Review

@nl

type

Item

label

Efficacy of Dasatinib in a CML ...... e Report and Literature Review

@ast

Efficacy of Dasatinib in a CML ...... e Report and Literature Review

@en

Efficacy of Dasatinib in a CML ...... e Report and Literature Review

@nl

prefLabel

Efficacy of Dasatinib in a CML ...... e Report and Literature Review

@ast

Efficacy of Dasatinib in a CML ...... e Report and Literature Review

@en

Efficacy of Dasatinib in a CML ...... e Report and Literature Review

@nl

P1476

Efficacy of Dasatinib in a CML ...... e Report and Literature Review

@en

P2093

E V Morozova

http://www.w3.org/2001/XMLSchema#string

K V Lepik

http://www.w3.org/2001/XMLSchema#string

M V Pryanishnikova

http://www.w3.org/2001/XMLSchema#string

Y Y Vlasova

http://www.w3.org/2001/XMLSchema#string

P2860

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options

Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation.

Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Chronic Myelogenous Leukemia, Version 1.2014

P304

43-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4137/BMI.S22438

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

Suppl 3

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Boris Afanasyev

P577

2015-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26673003

http://www.w3.org/2001/XMLSchema#string

P932

4674012

http://www.w3.org/2001/XMLSchema#string

Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review

about

P2860

P2860

Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932